London, UK – 04 August 2010

Proximagen announces sale of sabcomeline.

Annual Report 2009

Proximagen’s 2009 Annual Report has recently been published.

Investor Relations

Our investor relations centre is provided to give you convenient access to company information.

Share Price

Proximagen Group plc (Ticker: PRX) is listed on the London Stock Exchange’s Alternative Investment Market.

Proximagen's commitment to science is fundamental. We strive for true scientific innovation, breaking new ground in treatment.

Therapeutic Areas

Proximagen's vision is to become one of the world's leading companies developing therapeutics for patients suffering from diseases of the CNS.